KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2016 - 2025)

Jazz Pharmaceuticals has reported Income from Continuing Operations over the past 16 years, most recently at 203465000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations rose 6.47% to 203465000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 72382000.0 through Dec 2025, down 112.88% year-over-year, with the annual reading at 355459000.0 for FY2025, 163.28% down from the prior year.
  • Income from Continuing Operations was 203465000.0 for Q4 2025 at Jazz Pharmaceuticals, down from 251435000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 251435000.0 in Q3 2025 and troughed at 718384000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 70425000.0 (2023), against an average of 9106157.89.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 641.94% in 2022 and later skyrocketed 1109.01% in 2023.
  • Tracing JAZZ's Income from Continuing Operations over 5 years: stood at 32347000.0 in 2021, then plummeted by 641.94% to 239996000.0 in 2022, then soared by 139.42% to 94615000.0 in 2023, then skyrocketed by 101.98% to 191102000.0 in 2024, then grew by 6.47% to 203465000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 203465000.0, 251435000.0, and 718384000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.